Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Molecular Templates, Inc.MTEM · Entity 85987 | Director | June 03, 2021 | June 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Molecular Templates, Inc.
Report date June 03, 2021 · Filed June 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.98 · Expires 2031-06-03 | Direct | 15,000 |
Reported balance
After 2021-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-03 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the total number of shares subject to the option shall vest on June 3, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the total number of shares subject to the option shall vest on June 3, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2021 Filed Jun 4, 2021 16:30 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0000899243-21-022045 · doc4.xml · derivative · entry 1 Morenstein Scott D · CIK 0001576113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on June 3, 2022. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 17:06 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0000899243-20-014735 · doc4.xml · derivative · entry 1 Morenstein Scott D · CIK 0001576113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-28 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on May 28, 2021. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 16:24 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 468,750 | $8.00 | $3,750,000.00 |
DisclosureSEC source: 0000919574-19-007463 · ownership.xml · nonDerivative · entry 1 Morenstein Scott D · CIK 0001576113 · Director CDK ASSOCIATES, L.L.C. · CIK 0001576081 · Director CAXTON CORP · CIK 0001388551 · Director Kovner Bruce · CIK 0001325713 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,052,991 F1 · ownership.nature: These shares are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (iii) Scott Morenstein, a Managing Director of the investment manager of CDK Associates, LLC. F2 · ownership.nature: Scott Morenstein serves as a director of the Issuer. Caxton Corporation, Bruce Kovner and CDK Associates, L.L.C. may be considered directors by deputization due to their affiliation with Scott Morenstein. Each Reporting Person disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 29, 2019 Filed May 30, 2019 19:58 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0000899243-19-015227 · doc4.xml · derivative · entry 1 Morenstein Scott D · CIK 0001576113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-05-29 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on May 29, 2020. Read SEC document |
| December 26, 2018 Filed Dec 28, 2018 17:30 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 25,000 | $3.45 | $86,250.00 |
DisclosureSEC source: 0000919574-18-008210 · ownership.xml · nonDerivative · entry 1 CDK ASSOCIATES, L.L.C. · CIK 0001576081 · Director Morenstein Scott D · CIK 0001576113 · Director CAXTON CORP · CIK 0001388551 · Director Kovner Bruce · CIK 0001325713 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,584,241 F1 · ownership.direct: These shares are held by CDK Associates, L.L.C. and may be deemed to be beneficially owned by (i) Scott Morenstein, a Managing Director of Caxton Alternative Management LP, the investment manager of CDK Associates, L.L.C., (ii) Caxton Corporation, the manager of CDK Associates, LLC and (iii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Scott Morenstein serves as a director of the Issuer. Caxton Corporation, Bruce Kovner and CDK Associates, L.L.C. may be considered directors by deputization due to their affiliation with Scott Morenstein. Each Reporting Person disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 15:11 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 545,454 | $5.50 | $2,999,997.00 |
DisclosureSEC source: 0000899243-18-025415 · doc4.xml · nonDerivative · entry 1 Morenstein Scott D · CIK 0001576113 · Director CDK ASSOCIATES, L.L.C. · CIK 0001576081 · Director CAXTON CORP · CIK 0001388551 · Director Kovner Bruce · CIK 0001325713 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By CDK Associates, L.L.C. Disclosed balance after: 1,559,241 F1 · ownership.direct: These shares are held by CDK Associates, L.L.C. and may be deemed to be beneficially owned by (i) Scott Morenstein, a Managing Director of Caxton Alternative Management LP, the investment manager of CDK Associates, L.L.C., (ii) Caxton Corporation, the manager of CDK Associates, LLC and (iii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Scott Morenstein serves as a director of the Issuer. Caxton Corporation, Bruce Kovner and CDK Associates, L.L.C. may be considered directors by deputization due to their affiliation with Scott Morenstein. Each Reporting Person disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F1 · ownership.nature: These shares are held by CDK Associates, L.L.C. and may be deemed to be beneficially owned by (i) Scott Morenstein, a Managing Director of Caxton Alternative Management LP, the investment manager of CDK Associates, L.L.C., (ii) Caxton Corporation, the manager of CDK Associates, LLC and (iii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Scott Morenstein serves as a director of the Issuer. Caxton Corporation, Bruce Kovner and CDK Associates, L.L.C. may be considered directors by deputization due to their affiliation with Scott Morenstein. Each Reporting Person disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 16:23 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-18-014909 · doc4.xml · derivative · entry 1 Morenstein Scott D · CIK 0001576113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-31 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on May 31, 2019. Read SEC document |
| October 09, 2017 Filed Oct 11, 2017 19:01 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0000899243-17-024066 · doc4.xml · derivative · entry 1 Morenstein Scott D · CIK 0001576113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-10-09 F1 · derivative.exercise_date: 50% of the total number of shares subject to the option shall vest on each of October 9, 2018 and October 9, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.